Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study

Table 2 HIV (+) subject immunologic and HAART related characteristics

Immunologic characteristic	Mean ± SD	Range
Immunologic characteristic	Prevalence	Range
HIV History
Length of HIV diagnosis, months	196 ± 99	48–360
Previous history of AIDS-defining diagnosis, %	25	---
Previous history of opportunistic infections, %	19	---
Undetectable viral load > 3 years, %	100	---
Compliance with HAART > 3 years, %	99	90–100
HAART-induced side effects
Metabolic syndrome, %	22	---
Lipodystrophy, %	78	---
Lipoatrophy, %	63	---
Lipoaccumulation, %	67	---
HAART Exposure
Cumulative HAART (any agent), months	157 ± 88	36–336
Cumulative exposure PI, months	91 ± 57	0–249
Cumulative exposure NRTI, months	163 ± 122	40–464
Cumulative exposure “high risk” PI, months	47 ± 33	0–103
Cumulative exposure NNRTI, months^a	22 ± 63	0–156
Cumulative exposure INSTI, months^a	5.5 ± 12.6	0–48
Cumulative exposure “high risk” NRTI, months^a	44.2 ± 73.9	0–273
Immunologic History
CD4+ cell count^a	594 ± 326	242–2597
CD8+ cell count^a	686 ± 356	312–1944
CD4+/CD8+ ratio^a	78 ± 47	30–313

PI protease inhibitors, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, INSTI integrase strand transfer inhibitors, High risk PI’s amprenavir, fosampenavir, indinavir, lopinavir, High risk NRTI’s abacavir, didanosine
^aData reported as mean + standard deviation or median with interquartile range

ISSN: 1532-429X